ArticleFrontiers in oncology2025
Clinicopathologic characteristics and predictive nomogram of skip lymph node metastasis in gastric cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lymph node (LN) status is an independent factor affecting the prognosis of gastric cancer patients. Skip metastasis is a pattern of LN metastasis across a peritumoral (PT) area to an extra-peritumoral (EP) area. The purpose of the present study was to determine the clinical characteristics and establish a predictive nomogram for skip metastasis in gastric cancer. Methods: We reviewed the records of 1657 gastric cancer patients at the First Affiliated Hospital of China Medical University. The patients were categorized in four groups: only station II (skip group); only station I (PT-only group); station I and station II (PT+EP group); and no metastatic LNs (N0 group). The clinical characteristics between the skip group and the other three groups were compared. Results: The incidence of skip metastasis was 3.3% (55/1657) among the gastric cancer patients. The most common locations of skip metastasis were the No. 7 (50.9%), No. 8a (32.7%), No. 9 (21.8%), and No. 1 groups (20.0%). The skip group had significant differences compared to the PT+EP group in pN stage, Borrmann type, pT stage and location, as predictors in the nomogram for prediction of skip metastasis. The area under the ROC curve was 0.908. Conclusions: This study identified key risk factors for skip lymph node metastasis and developed the first clinically applicable predictive model. The resulting nomogram demonstrated high accuracy in risk stratification, providing a visual tool to optimize lymph node dissection strategies. These findings support incorporating metastatic location into gastric cancer staging systems and the location of LN metastasis should be considered to improve the LN staging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.